Neurology encompasses a very wide range of diseases such as multiple Sclerosis (MS), Parkinson’s but also Oncology. Many of the diseases in this therapeutic area are being treated with some form of immunomodulating therapy.

Our immune monitoring assays are excellent tools to screen for effects on the immune system. Our inter disciplany approach and experts can help setting up effective immune monitoring to unravel the effects of a therapeutic drug in development.

• Flow Cytometry
• Antigen specific T cell analysis (Cellular assays)
• Innate cellular assays

References

Gelissen LMY, Wijburg MT, Strijbis EMM, van Oosten BW, de Jong BA, Uitdehaag BMJ, Rispens T, Feltkamp MCW, van Kempen ZLE, Killestein J. Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis. JAMA Neurol. 2025 May 1;82(5):523-525. doi: 10.1001/jamaneurol.2025.0337. Erratum in: JAMA Neurol. 2025 May 1;82(5):529. doi: 10.1001/jamaneurol.2025.1468. PMID: 40163140; PMCID: PMC11959470.

Rispens T, Leeuwen Av, Vennegoor A, Killestein J, Aalberse RC, Wolbink GJ, Aarden LA. Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal Biochem. 2011 Apr 15;411(2):271-6. doi: 10.1016/j.ab.2011.01.001. Epub 2011 Jan 7. PMID: 21216215.